Abstract:The proteolysis targeting chimeras (PROTACs) approach has attracted extensive attention in the past decade, which represents an emerging therapeutic modality with the potential to tackle disease-causing proteins that are historically challengeable for conventional small molecular inhibitors. PROTAC harnesses the endogenic E3 ubiquitin ligase to degrade protein of interest (POI) via ubiquitin-proteasome system in a cycle-catalytic manner. The event-driven pharmacology of PROTAC is poised to pursue those targets that are conventionally undruggable, which enormously extends the space of drug development. Furthermore, PROTAC has the potential to address drug resistance of small molecular inhibitors by degrading the whole POI. Nevertheless, PROTACs display high-efficiency and always-on properties to degrade POI, they may cause severe side effects due to an "on-target but off-tissue" protein degradation profile at the undesirable tissues and cells. Given that, the stimuli-activatable PROTAC prodrugs have been recently exploited to confine precise protein degradation of the favorable targets, which may conquer the adverse effects of PROTAC due to uncontrollable protein degradation. Herein, we summarized the cutting-edge advances of the stimuli-activatable PROTAC prodrugs. We also overviewed the progress of PROTAC prodrug-based nanomedicine to improve PROTAC delivery to the tumors and precise POI degradation in the targeted cells.

Conditionally Activatable Chimeras for Tumor-Specific Membrane Protein Degradation

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation

Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Precise Modulation of Protein Degradation by Smart PROTACs

Design of Murine Double Minute 2 Proteolysis Targeting Chimera Degraders with a Built-In Tumor-Targeting Ability

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Peptide-Mediated Small Molecule Lysosome-Targeting Chimeras for Targeted Degradation of Membrane and Intracellular Proteins

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

Mitochondrial Protease Targeting Chimeras for Mitochondrial Matrix Protein Degradation

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death

Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation

Targeted protein degradation in cancers: Orthodox PROTACs and beyond